1
|
Auat M, Cardoso CC, Santos-Pirath IM, Rudolf-Oliveira RCM, Matiollo C, Lange BG, da Silva JP, Dametto GC, Pirolli MM, Colombo MDHP, Santos-Silva MC. Evaluation of CD307a expression patterns during normal B-cell maturation and in B-cell malignancies by flow cytometry. CYTOMETRY PART B-CLINICAL CYTOMETRY 2018; 94:588-595. [DOI: 10.1002/cyto.b.21631] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Received: 08/02/2017] [Revised: 01/14/2018] [Accepted: 02/20/2018] [Indexed: 11/06/2022]
Affiliation(s)
- Mariangeles Auat
- Postgraduate Program in Pharmacy of the Federal University of Santa Catarina; Florianópolis, Santa Catarina Brazil
| | - Chandra Chiappin Cardoso
- Clinical Analysis Division; University Hospital of the Federal University of Santa Catarina, Florianópolis; Santa Catarina Brazil
| | - Iris Mattos Santos-Pirath
- Postgraduate Program in Pharmacy of the Federal University of Santa Catarina; Florianópolis, Santa Catarina Brazil
- Clinical Analysis Division; University Hospital of the Federal University of Santa Catarina, Florianópolis; Santa Catarina Brazil
| | | | - Camila Matiollo
- Clinical Analysis Division; University Hospital of the Federal University of Santa Catarina, Florianópolis; Santa Catarina Brazil
| | - Bárbara Gil Lange
- Clinical Analysis Department of the Federal University of Santa Catarina, Florianópolis; Santa Catarina Brazil
| | - Jessica Pires da Silva
- Clinical Analysis Department of the Federal University of Santa Catarina, Florianópolis; Santa Catarina Brazil
| | | | - Mayara Marin Pirolli
- Hematology and Hemotherapy Center of Santa Catarina, Florianópolis; Santa Catarina Brazil
| | | | - Maria Claudia Santos-Silva
- Postgraduate Program in Pharmacy of the Federal University of Santa Catarina; Florianópolis, Santa Catarina Brazil
- Clinical Analysis Division; University Hospital of the Federal University of Santa Catarina, Florianópolis; Santa Catarina Brazil
- Clinical Analysis Department of the Federal University of Santa Catarina, Florianópolis; Santa Catarina Brazil
| |
Collapse
|
2
|
Orentas RJ, Nordlund J, He J, Sindiri S, Mackall C, Fry TJ, Khan J. Bioinformatic description of immunotherapy targets for pediatric T-cell leukemia and the impact of normal gene sets used for comparison. Front Oncol 2014; 4:134. [PMID: 24959420 PMCID: PMC4050364 DOI: 10.3389/fonc.2014.00134] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [Key Words] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/15/2014] [Accepted: 05/21/2014] [Indexed: 11/13/2022] Open
Abstract
Pediatric lymphoid leukemia has the highest cure rate of all pediatric malignancies, yet due to its prevalence, still accounts for the majority of childhood cancer deaths and requires long-term highly toxic therapy. The ability to target B-cell ALL with immunoglobulin-like binders, whether anti-CD22 antibody or anti-CD19 CAR-Ts, has impacted treatment options for some patients. The development of new ways to target B-cell antigens continues at rapid pace. T-cell ALL accounts for up to 20% of childhood leukemia but has yet to see a set of high-value immunotherapeutic targets identified. To find new targets for T-ALL immunotherapy, we employed a bioinformatic comparison to broad normal tissue arrays, hematopoietic stem cells (HSC), and mature lymphocytes, then filtered the results for transcripts encoding plasma membrane proteins. T-ALL bears a core T-cell signature and transcripts encoding TCR/CD3 components and canonical markers of T-cell development predominate, especially when comparison was made to normal tissue or HSC. However, when comparison to mature lymphocytes was also undertaken, we identified two antigens that may drive, or be associated with leukemogenesis; TALLA-1 and hedgehog interacting protein. In addition, TCR subfamilies, CD1, activation and adhesion markers, membrane-organizing molecules, and receptors linked to metabolism and inflammation were also identified. Of these, only CD52, CD37, and CD98 are currently being targeted clinically. This work provides a set of targets to be considered for future development of immunotherapies for T-ALL.
Collapse
Affiliation(s)
- Rimas J Orentas
- Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health , Bethesda, MD , USA
| | - Jessica Nordlund
- Molecular Medicine, Department of Medical Sciences and Science for Life Laboratory, Uppsala University , Uppsala , Sweden
| | - Jianbin He
- Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health , Bethesda, MD , USA
| | - Sivasish Sindiri
- Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health , Bethesda, MD , USA
| | - Crystal Mackall
- Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health , Bethesda, MD , USA
| | - Terry J Fry
- Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health , Bethesda, MD , USA
| | - Javed Khan
- Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health , Bethesda, MD , USA
| |
Collapse
|